These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1441695)

  • 41. Pimobendan and its use in treating canine congestive heart failure.
    Bowles D; Fry D
    Compend Contin Educ Vet; 2011 Nov; 33(11):E1. PubMed ID: 22101450
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acute hemodynamics of pimobendan in chronic heart failure. A comparative crossover study of captopril and pimobendan.
    Tsuda T; Izumi T; Kodama M; Hanawa H; Takahashi M; Suzuki M; Aizaki T; Uchiyama H; Kuwano H; Shibata A
    Jpn Heart J; 1992 Mar; 33(2):193-203. PubMed ID: 1593749
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of pimobendan in addition to standard therapy for heart failure on prevention of readmission in elderly patients with severe chronic heart failure.
    Kawano H; Arakawa S; Satoh O; Matsumoto Y; Hayano M; Nakatomi D; Yamasa T; Maemura K
    Geriatr Gerontol Int; 2014 Jan; 14(1):109-14. PubMed ID: 23581555
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
    Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy.
    O'Grady MR; Minors SL; O'Sullivan ML; Horne R
    J Vet Intern Med; 2008; 22(4):897-904. PubMed ID: 18537880
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A review of the pharmacology and clinical uses of pimobendan.
    Boyle KL; Leech E
    J Vet Emerg Crit Care (San Antonio); 2012 Aug; 22(4):398-408. PubMed ID: 22928748
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of oral administration of pimobendan in cats with heart failure.
    Gordon SG; Saunders AB; Roland RM; Winter RL; Drourr L; Achen SE; Hariu CD; Fries RC; Boggess MM; Miller MW
    J Am Vet Med Assoc; 2012 Jul; 241(1):89-94. PubMed ID: 22720992
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A; Häggström J; Gordon SG; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Watson P
    J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure.
    Hagemeijer F
    Eur Heart J; 1993 Apr; 14(4):551-66. PubMed ID: 8472722
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Ablad B; Bussadori CM; Glaus T; Kovacević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir AV; O'Sullivan ML; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2008; 22(5):1124-35. PubMed ID: 18638016
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative effects of ibopamine and captopril in mild congestive heart failure. Focus on the long-term effects of inodilation on ventricular arrhythmias.
    Cocchieri M; Alunni GF; Del Favero A; Fortunati F; Bardelli G; Capponi EA; Regi L; Boschetti E
    Cardiology; 1990; 77 Suppl 5():36-42. PubMed ID: 2126222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure.
    Kubo SH
    Cardiology; 1997; 88 Suppl 2():21-7. PubMed ID: 9142432
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of imazodan for treatment of chronic congestive heart failure. The Imazodan Research Group.
    Goldberg AD; Nicklas J; Goldstein S
    Am J Cardiol; 1991 Sep; 68(6):631-6. PubMed ID: 1715125
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inotropic agents with calcium-sensitizing properties: clinical and hemodynamic effects of pimobendan.
    Kubo SH
    Coron Artery Dis; 1994 Feb; 5(2):119-26. PubMed ID: 8180743
    [No Abstract]   [Full Text] [Related]  

  • 56. Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis.
    Okamoto N; Kubo T; Nakashima Y; Ochi Y; Takahashi A; Baba Y; Hirota T; Yamasaki N; Kitaoka H
    Intern Med; 2020 Feb; 59(3):339-343. PubMed ID: 31588087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
    Boswood A; Gordon SG; Häggström J; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
    J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pimobendan in heart failure therapy--a silver bullet?
    Gordon SG; Miller MW; Saunders AB
    J Am Anim Hosp Assoc; 2006; 42(2):90-3. PubMed ID: 16527909
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Hagemeijer F; Brand HJ; van Mechelen R
    Am J Cardiol; 1989 Mar; 63(9):571-6. PubMed ID: 2919561
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure.
    Reina-Doreste Y; Stern JA; Keene BW; Tou SP; Atkins CE; DeFrancesco TC; Ames MK; Hodge TE; Meurs KM
    J Am Vet Med Assoc; 2014 Sep; 245(5):534-9. PubMed ID: 25148095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.